This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05796/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05796/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05796/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05796
rdf:type
n3:Drug
n3:description
SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for the treatment of essential hypertension and congestive heart failure and it is in the phase II of clinical trails.
n3:generalReferences
# Tabrizchi R: SLV-306. Solvay. Curr Opin Investig Drugs. 2003 Mar;4(3):329-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12735234
n3:group
investigational
n3:indication
Investigated for use/treatment in congestive heart failure and hypertension.
owl:sameAs
n7:DB05796
dcterms:title
SLV 306
adms:identifier
n9:3038505 n10:2302069 n11:DB05796
n3:mechanismOfAction
SLV306 increased plasma natriuretic peptides and big endothelin-1 levels in a dose-dependent manner, confirming neutral endopeptidase and endothelin-converting enzyme inhibition. The combined inhibition of neutral endopeptidase and endothelin-converting enzyme may be useful in heart failure by reducing right and left cardiac filling pressures
n3:IUPAC-Name
n4:271B46C1-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B46C7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B46C6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B46C3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B46C4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B46C5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B46BF-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B46BD-363D-11E5-9242-09173F13E4C5 n4:271B46C0-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B46BE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B46CD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B46CE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B46C8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B46C9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B46CB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B46CA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B46CC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B46D3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B46D5-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B46D6-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B46D2-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B46D1-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B46D4-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B46C2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B46CF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B46D0-363D-11E5-9242-09173F13E4C5